Okuda D T, Srinivasan R, Oksenberg J R, Goodin D S, Baranzini S E, Beheshtian A, Waubant E, Zamvil S S, Leppert D, Qualley P, Lincoln R, Gomez R, Caillier S, George M, Wang J, Nelson S J, Cree B A C, Hauser S L, Pelletier D
UCSF Multiple Sclerosis Center, University of California, San Francisco, San Francisco, California 94117, USA.
Brain. 2009 Jan;132(Pt 1):250-9. doi: 10.1093/brain/awn301. Epub 2008 Nov 20.
Genetic susceptibility to multiple sclerosis (MS) is associated with the human leukocyte antigen (HLA) DRB11501 allele. Here we show a clear association between DRB11501 carrier status and four domains of disease severity in an investigation of genotype-phenotype associations in 505 robust, clinically well characterized MS patients evaluated cross-sectionally: (i) a reduction in the N-acetyl-aspartate (NAA) concentration within normal appearing white matter (NAWM) via (1)HMR spectroscopy (P = 0.025), (ii) an increase in the volume of white matter (WM) lesions utilizing conventional anatomical MRI techniques (1,127 mm(3); P = 0.031), (iii) a reduction in normalized brain parenchymal volume (nBPV) (P = 0.023), and (iv) impairments in cognitive function as measured by the Paced Auditory Serial Addition Test (PASAT-3) performance (Mean Z Score: DRB11501+: 0.110 versus DRB11501-: 0.048; P = 0.004). In addition, DRB11501+ patients had significantly more women (74% versus 63%; P = 0.009) and a younger mean age at disease onset (32.4 years versus 34.3 years; P = 0.025). Our findings suggest that DRB11501 increases disease severity in MS by facilitating the development of more T2-foci, thereby increasing the potential for irreversible axonal compromise and subsequent neuronal degeneration, as suggested by the reduction of NAA concentrations in NAWM, ultimately leading to a decline in brain volume. These structural aberrations may explain the significant differences in cognitive performance observed between DRB1*1501 groups. The overall goal of a deep phenotypic approach to MS is to develop an array of meaningful biomarkers to monitor the course of the disease, predict future disease behaviour, determine when treatment is necessary, and perhaps to more effectively recommend an available therapeutic intervention.
多发性硬化症(MS)的遗传易感性与人类白细胞抗原(HLA)DRB11501等位基因相关。在此,我们在一项针对505例病情稳定、临床特征明确的MS患者的横断面基因型-表型关联研究中,展示了DRB11501携带者状态与疾病严重程度的四个领域之间存在明确关联:(i)通过氢磁共振波谱法((1)HMR spectroscopy)显示正常外观白质(NAWM)内N-乙酰天门冬氨酸(NAA)浓度降低(P = 0.025);(ii)利用传统解剖MRI技术显示白质(WM)病变体积增加(1,127立方毫米;P = 0.031);(iii)标准化脑实质体积(nBPV)降低(P = 0.023);以及(iv)通过定速听觉连续加法测验(PASAT-3)表现测量的认知功能受损(平均Z分数:DRB11501+:0.110对比DRB11501-:0.048;P = 0.004)。此外,携带DRB11501的患者女性明显更多(74%对比63%;P = 0.009),且疾病发病时的平均年龄更小(32.4岁对比34.3岁;P = 0.025)。我们的研究结果表明,DRB11501通过促进更多T2病灶的形成增加了MS的疾病严重程度,从而增加了不可逆轴突损伤及随后神经元变性的可能性,如NAWM中NAA浓度降低所提示的,最终导致脑体积减小。这些结构异常可能解释了DRB1*1501组之间观察到的认知表现的显著差异。深入表型分析方法研究MS的总体目标是开发一系列有意义的生物标志物,以监测疾病进程、预测未来疾病行为、确定何时需要治疗,并可能更有效地推荐可用的治疗干预措施。